Filtered By:
Condition: ALS
Drug: Lithium
This page shows you your search results in order of date.
Order by Relevance | Date
Total 60 results found since Jan 2013.
An Increase in Peroxiredoxin 6 Expression Induces Neurotoxic A1 Astrocytes in the Lumbar Spinal Cord of Amyotrophic Lateral Sclerosis Mice Model
In this study, we observed that the expression of peroxiredoxin 6 (PRDX6), a member of the peroxiredoxin family, was markedly upregulated in astrocytes of the lumbar spinal cord of SOD1G93A mice model for ALS. Additionally, when PRDX6 was transiently transfected into the mouse astrocyte cell line C8-D1A and human astrocytoma cell line U-251 MG, the mRNA expression of complement C3 (a marker for A1 astrocyte phenotype) and inflammatory cytokines was increased. Furthermore, the mRNA expression of C3 and inflammatory cytokine was increased in C8-D1A and U-251 MG cells stably expressing PRDX6, and the increased mRNA expression...
Source: Neurochemical Research - August 9, 2023 Category: Neuroscience Authors: Akiko Yamamuro-Tanabe Yurika Mukai Wataru Kojima Siyuan Zheng Naoko Matsumoto Shoho Takada Mao Mizuhara Yasuhiro Kosuge Yuki Ishimaru Yasuhiro Yoshioka Source Type: research
What lithium holds in epilepsy?
Curr Neuropharmacol. 2022 Apr 11. doi: 10.2174/1570159X20666220411081728. Online ahead of print.ABSTRACTLithium is a well-known FDA approved treatment for bipolar and mood disorders. Lithium has been an enigmatic drug with multifaceted actions involving various neurotransmitters and intricate cell signalling cascades. Recent studies highlight the neuroprotective and neurotrophic actions of lithium in amyotrophic lateral sclerosis, Alzheimer's disease, intracerebral hemorrhage, and epilepsy. Of note, lithium holds a significant interest in epilepsy, where the past reports expose its non-specific proconvulsant action, follow...
Source: Current Neuropharmacology - April 12, 2022 Category: Drugs & Pharmacology Authors: Sree Lalitha Bojja Neha Singh Kiran Kumar Kolathur C Mallikarjuna Rao Source Type: research
